Processa Pharmaceuticals (OTCMKTS: PCSA) was formed in October 2017 as a
result of an asset acquisition of Promet Therapeutics, LLC by Heatwurx,
Inc (OTCMKTS: HUWX). Processa's mission is to develop products that can
improve the survival and/or quality of life for patients who have a
high unmet medical need.